Looks like this event has already ended.
Check out upcoming events by this organizer, or organize your very own event.
San Francisco, California
London, United Kingdom
The Board of California Antiviral Foundation – John Fiddes PhD, Roberta Lee MD, Constance McKee and Michael Siani-Rose – invite you to join us on September 20, 2012 at the Delancey Street Foundation.
Reception from 6pm – 8pm in the Screening Room (Auditorium)
600 Embarcadero, San Francisco, CA 94114
Host Committee – Bob Barrett, Darryl Flick, Kile Ozier, Stephen Suzman
Our special guests – Joining us to discuss innate immunity to HIV/AIDS are Jay A. Levy MD, Professor of Medicine, UCSF, and two "long-term survivors."
Refreshments - hors d'oeuvres and beverages will be served. Children are welcome (no childcare for toddlers).
Why we are fundraising - We can translate CAF into a drug so that its anti-HIV effects work on the 95% of HIV-infected individuals who do not produce it naturally.
After more than 20 years, science is closing in on this elusive factor. We could see first data in patients within five years. Join us to support this effort.
Our mission is to make a CAF-derived drug affordable and available to all HIV-infected individuals worldwide.
When & Where
California Antiviral Foundation
We are a nonprofit 501(c)3 organization whose mission is to find CAF, the Factor underlying innate immunity to AIDS, translate CAF into a drug, and make an affordable CAF-based drug available to all HIV-infected individuals worldwide.
We have all the technical expertise and resources available to us, and all the business infrastructure set up to support our mission. Now it's just a question of financial resources to accelerate the pace at which we work in partnership with the University of California, San Francisco.
Our project gratefully acknowledges and carefully leverages the years of research supported by the NIH and by private foundations. If we had all the resources we need, we could see first data in patients in five years. At least 90% of all donations will be spent to support the science and development of a CAF-based drug.